Year: 2026

DENVER, March 30, 2026 (GLOBE NEWSWIRE) — American Rare Earths (ASX: ARR | OTCQX: ARRNF | ADR: AMRRY) (“ARR” or the “Company”) is pleased to announce that it has engaged Tetra Tech, a U.S. based major consulting and engineering services company, to complete an Oxides to Metals study for the Company’s heavy rare earths (“HREE”) stream. The study will evaluate options to convert separated heavy rare earth oxides from the American Rare Earths Halleck Creek Project in Wyoming all the way to metal, a critical midstream step immediately preceding the manufacture of permanent magnets relied upon by defense and advanced technology sectors. Positioning into the U.S. midstream Today, China dominates the midstream of the rare earth value chain, including oxide separation and metal production. The United States has prioritized development of...

Teva’s biosimilar, PONLIMSI™, is now FDA-approved across all indications of the reference product, Prolia® (denosumab), to treat a variety of debilitating bone conditions. Teva’s proposed biosimilar candidate to Xolair® (omalizumab) is accepted for review by U.S. FDA and EU EMA. These milestones demonstrate Teva’s biosimilars expertise and are a significant step in Teva’s Pivot to Growth strategy, highlighting its transformation into a leading biopharmaceutical company with a broad biosimilars portfolio.TEL AVIV, Israel and PARSIPPANY, N.J., March 30, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced three milestones in its biosimilar portfolio, demonstrating continued momentum in the advancement of its Pivot to Growth strategy. The United States (U.S.) Food and Drug Administration...

Using its pioneering AI-platform, AI-Immunology™, Evaxion has, in collaboration with the Gates Foundation, developed novel design concepts for polio vaccines potentially superior to those currently used The AI-Immunology™ concepts include hybrid capsid designs and de novo designed B-cell antigen approaches Despite polio vaccines being available for decades, the highly infectious viral disease continues to pose a global health risk Evaxion will also present data from its EVX-V1 vaccine program targeting cytomegalovirus at the World Vaccine CongressCOPENHAGEN, Denmark, March 30, 2026 – Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, has in collaboration with the Gates Foundation developed novel and potentially superior...

Dialogue continues with European Medicines Agency (EMA) to advance the development program of oral blarcamesine in early Alzheimer’s disease Additional data submitted to the U.S. FDA with the objective to discuss potential pathways towards a New Drug Application (NDA) for the treatment of early Alzheimer’s disease Additionally, Anavex has engaged in discussions with EU regulators regarding blarcamesine for Parkinson’s disease and rare diseases, including Rett syndrome NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other...

Intersection includes 23.9m of 1.72 g/t gold, 7.15m of 3.46 g/t gold, and 16m of 0.07 g/t gold* Exploration further expands gold mineralization at Juby Gold Project on Golden Lake Deposit TORONTO, March 30, 2026 (GLOBE NEWSWIRE) — McFarlane Lake Mining Limited (“McFarlane” or the “Company”) (CSE: MLM, OTC: MLMLF, FRA: W2Z) is pleased to announce further results from its diamond drilling exploration campaign being conducted on its 100%-owned Juby Gold Project, located west of Gowganda, Ontario, within the southern part of the “Abitibi Greenstone Belt”. Drilling was initiated in December 2025 on the property and commenced at the Company’s 826 Zone and has now moved to the Golden Lake Zone, see Figure 1. HighlightsDrill hole GL 76-72 at Golden Lake has intersepted 0.95 g/t gold over 92.6m, this includes 23.9m of 1.72 g/t gold and...

CALGARY, Alberta, March 30, 2026 (GLOBE NEWSWIRE) — Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company”), a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, today announced it has secured non-dilutive funding from the Alberta Innovates CarE (AICE) market access program to support the Phase I testing of its lead compound, MB-204. The $600,000 AICE-funded project represents a significant contribution toward the overall cost of the Phase I clinical trial of MB-204 and supports the advancement of the program into human trials. The AICE program is highly competitive and subject to rigorous peer review, providing strong third-party validation of the scientific and commercial potential...

The approval was anchored on data from the pivotal DEVOTE study that investigated the efficacy and safety of the High Dose Regimen of SPINRAZA in treatment-naïve and previously treated SPINRAZA patients High Dose SPINRAZA will be available in the United States in the coming weeks and is also approved in the European Union, Switzerland and JapanCAMBRIDGE, Mass., March 30, 2026 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced that the High Dose Regimen of SPINRAZA® (nusinersen), which is comprised of 50 mg/5 mL and 28 mg/5 mL doses, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of spinal muscular atrophy (SMA). Backed by more than 10 years of clinical data supporting the Low Dose Regimen of SPINRAZA (12 mg), High Dose SPINRAZA was designed to deliver a higher concentration of drug through...